SARS-CoV-2 vaccination predicts COVID-19 progression and outcomes in hospitalized patients

  1. Alessandro Padovani
  2. Viviana Cristillo
  3. Daniela Tomasoni
  4. Stefano Gipponi
  5. Andrea Pilotto

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Background

SARS-CoV-2 vaccination might impact on clinical progression of cases with breakthrough COVID-19 disease.

Objective

to evaluate the impact of SARS-CoV-2 vaccination on disease progression in COVID-19 hospitalized patient

Methods and Findings

Two-hundred eighty-four consecutive COVID-19 hospitalized patients, including 50 vaccinated cases entered the study. Compared to unvaccinated cases, vaccinated patients were older, exhibited more comorbidities and did not differ for COVID-19 severity at admission. During hospitalisation, unvaccinated patients showed worse disease progression, including higher need of oxygen and higher risk of death compared to vaccinated patients (OR 3.3; 1.05-10.7 95% CI in the whole cohort and OR 54.8; 3.5-852 in the ventilated cases).

Discussion

These findings argue for an important reduction in severity among vaccine breakthrough infection compared to unvaccinated cases in COVID-19 disease.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.11.21.21266633: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The study received approval from local ethics committee of the ASST Spedali Civili Hospital, Brescia (NP 4067, approved 08.05. 2020).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    As main limitation of the present study, we did not evaluate the IgG antibodies title data for immunized patients, which might be associate with different degree of systemic and respiratory immune response to SASR-CoV-2 infection. We also acknowledged that the statistical models were limited by the small sample size and that multivariate analyses including prognostic factors or propensity algorithms need to be implemented in on-going multi-center prospective studies. Limitations notwithstanding, our findings argue for a beneficial role of vaccination beyond the prevention of the disease, that dramatically impact on clinical progression and outcomes in COVID-19 disease.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.11.21.21266633v1 on medRxiv